Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)
about
sameAs
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyEnoxaparin in acute coronary syndromesClinical application of enoxaparin.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.Heparin in interventional radiology: a therapy in evolutionLow-molecular-weight heparins: pharmacoeconomic decision modeling based on meta-analysis data.Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryReview of enoxaparin and its clinical applications in venous and arterial thromboembolism.Optimizing adjunctive antithrombotic therapy in the treatment of acute myocardial infarction: a role for low-molecular-weight heparin.Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction.Overview of contemporary reperfusion strategies in acute ST-elevation myocardial infarction.Utilizing enoxaparin in the management of STEMI.New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implicationsEfficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction.Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.Safety evaluation of enoxaparin in currently approved indications.Enoxaparin: a pharmacologic and clinical review.Cost effectiveness of anticoagulation in acute coronary syndromes.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis.ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
P2860
Q28239975-D9D7B067-34AA-4CBA-8522-8B7CF22B89C6Q28301431-976247A6-8BCE-4128-BCAC-9BAF3317449CQ33360866-EB8A3A69-0965-4E3A-B376-14085116984FQ33360869-1D78156D-1280-4256-A439-7DE016EA9E3FQ33394179-688461DF-A7B0-4125-8452-1A81BDD751AFQ33618610-C36C93E5-0DC8-439B-8C05-54E58553BDB9Q34196711-E10D20C2-379F-4590-B9FF-A5D75FE310ACQ34628623-3800EF18-08D2-43FC-9012-BF4B17671E35Q35638777-D70AAB92-C030-418C-B320-409E918D44A3Q36035257-5F374F28-3FE0-43C6-99B8-A01C447701F6Q36216834-577E16D8-33A8-4C15-8F5A-D27E8FB04E9AQ37031371-148A6571-0374-41D3-97F2-9EF2FB3A33C1Q37193906-C9719B12-EC5A-45C1-8BCA-5DB1F17B3773Q37414802-AD72B28B-34F1-4929-BE18-446A1CF43545Q37445888-07FBFC15-C5B6-4F08-A784-6D8B33A668D8Q37622250-169E11DA-799D-4294-82DB-2F607C4F5A09Q37862264-8C6ADF54-FF32-4BCD-88DD-6F8AFCA12F8FQ37992680-0A4C10E7-5576-4133-A202-55D4CE7993F8Q37997963-1270C4F9-B014-4B18-A935-5105E3208356Q41807158-355382BD-F988-4FF1-9960-86B94936F3BEQ44517148-F1AD5549-A9A6-4591-B997-C22771207831Q47365108-05754C58-A02D-451E-871B-CDD379E8D813Q50665407-841DF279-CFE1-4AD1-A185-03EC36B56AB6
P2860
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@ast
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@en
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@nl
type
label
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@ast
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@en
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@nl
prefLabel
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@ast
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@en
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@nl
P2093
P356
P1433
P1476
Randomized comparison of enoxa ...... Reperfusion Therapy (HART II)
@en
P2093
C Lundergan
L Regalado
M Knudtson
V Le Louer
W Schwartz
P304
P356
10.1161/HC3101.093866
P407
P577
2001-08-07T00:00:00Z